Clozapine Induced Hypersalivation (Sialorrhoea) – Clinical Importance and Pharmacological Options for Management
Key Points
Clozapine-induced hypersalivation, or clozapine-induced sialorrhoea, is a common and clinically important adverse effect that can affect adherence, sleep, quality of life, and treatment continuation.
Although clozapine is an evidence-based treatment for treatment-resistant schizophrenia, hypersalivation should be proactively assessed because it may contribute to distress, embarrassment, insomnia, aspiration risk, and non-adherence.
The mechanisms of clozapine-induced hypersalivation are multifactorial and may involve M4 muscarinic agonism, alpha-2 antagonism, unopposed beta-adrenergic activity, reduced laryngeal peristalsis, and impaired swallowing.
Initial management should include non-pharmacological strategies, assessment of timing and severity, clozapine dose review, clozapine level assessment, and consideration of interacting medications such as CYP1A2 inhibitors.
Pharmacological management of clozapine-induced sialorrhoea includes options such as sublingual atropine, hyoscine, anticholinergic agents, and non-anticholinergic strategies, but the evidence base includes case reports, case series, and limited randomised controlled trial data.
Clinicians should balance symptomatic control against anticholinergic burden, particularly because clozapine already carries risks of constipation, cognitive impairment, blurred vision, sedation, and gastrointestinal hypomotility.
Amisulpride has been proposed as an alternative strategy for clozapine-induced hypersalivation and may be useful in selected patients where anticholinergic burden is a concern or clozapine dose reduction is clinically feasible.
Clozapine is an evidence-based treatment in treatment-resistant schizophrenia. It is known to reduce all-cause mortality in schizophrenia and also has anti-suicidal effects. Clozapine’s efficacy has to be weighed up against rare serious side effects such as agranulocytosis, myocarditis, cardiomyopathy and thromboembolic phenomenon. [Cardiac complications of clozapine]
Common side effects such as weight gain and hypersalivation can affect compliance and therefore should be proactively managed.
Approximately 30%-80% of patients report hypersalivation as a side effect. One study reported a rate of 91%. [Maher S et al., 2016]
Day time drooling is reported as the top three adverse effects with clozapine.
It is associated with significant distress, social embarrassment, low self-esteem, insomnia and in severe cases can lead to aspiration pneumonia. It is one of the important factors associated with non-adherence to clozapine. [Gupta s et al., 2020]
Enhance Your Psychiatry Practice
Join The Academy by Psych Scene and earn CME & CPD points from 150+ hours of expert-led psychiatry courses. Hub Pro Included ✅
Check out our courses
MECHANISMS OF CLOZAPINE INDUCED HYPERSALIVATION
- M4 muscarinic receptor agonism
- Alpha-2 receptor antagonism
- Unopposed beta-adrenoceptors activity secondary to alpha-1 and alpha-2 antagonism
- Decreased laryngeal peristalsis
- Decreased swallowing via reduction of GI motility
Rating Scales:
- Nocturnal Hypersalivation Rating Scale
- Drooling Severity and Frequency Scale
MANAGEMENT OF CLOZAPINE INDUCED HYPERSALIVATION
Non-Pharmacological Interventions:
Daytime:
- Chewing sugarless gums may reduce hypersalivation as it promotes swallowing.
Nighttime:
- Covering the pillow with a towel
- Elevating the head and sleeping on the side reduces sleep disruption and risk of aspiration.
Pharmacological management
1. Wait and watch:
- Clozapine-induced hypersalivation occurs in the early stage of treatment and can reduce in severity over time.
2. Review clozapine dose as hypersalivation may be dose-related
3. Clozapine level:
- Consider medications that may increase clozapine levels, e.g., CYP1A2 inhibitors.
4. Reduce dose if possible with close monitoring for relapse.
5. Augmentation strategies:
-
There are a range of augmentation strategies for clozapine-induced sialorrhoea, with evidence derived mainly from case reports, case series and a small number of randomised controlled trials.
-
Amisulpride 100–400 mg/day has been proposed as an alternative to anticholinergic agents and may also allow clozapine dose reduction.
-
Common clinical strategies include the addition of anticholinergic agents such as atropine and hyoscine. However, clinicians should remain mindful of the cumulative anticholinergic burden, particularly constipation, cognitive impairment, blurred vision and urinary retention.
-
Sublingual atropine 1% eye drops are used off-label for clozapine-induced sialorrhoea, usually as one to two drops administered sublingually at night or once to twice daily. The aim is to achieve a local antimuscarinic effect while reducing systemic anticholinergic burden. However, the evidence base remains limited, with earlier data largely confined to case reports and case series. [Van der Poorten & De Hert, 2019]
-
A retrospective chart review of 161 inpatients receiving or commencing clozapine found clozapine-induced hypersalivation in 42% of patients. Local antimuscarinic strategies, including tropicamide and atropine drops, were associated with a median 33% reduction in wet pillow patch diameter after first-step treatment, with no serious adverse events reported in this monitored inpatient setting. [Mutlu et al, 2024]
-
Some centres have used atropine or tropicamide drops as a mouthwash approach, aiming to maximise local antimuscarinic benefit while limiting systemic exposure. As these preparations are ophthalmic and the indication is off-label, treatment should be framed as an individual therapeutic trial, with explicit review of response, adverse effects and ongoing need.
Safety considerations with sublingual atropine
Clinicians should not assume that sublingual administration is pharmacologically benign. Sublingual absorption may bypass first-pass metabolism and increase systemic exposure. This is clinically relevant because atropine toxicity may occur with dosing errors or accidental ingestion, particularly when eye-drop bottles can be emptied with relative ease. [Therapeutic Goods Administration, 2018]
Atropine eye drops are not approved in Australia for the treatment of hypersalivation. The Therapeutic Goods Administration has advised caution with off-label use after a coronial case in which an adult patient died following accidental oral ingestion of atropine eye drops prescribed for sublingual administration. [Therapeutic Goods Administration, 2018]
The key clinical risk is that a “drop-based” dose is supplied as a concentrated liquid in a bottle, creating the potential for overdose if the bottle is squeezed or ingested. When atropine is used, clinicians should document off-label use, obtain informed consent, provide written and verbal dosing instructions, and consider carer involvement where appropriate.
Monitoring should include anticholinergic adverse effects such as dry mouth, blurred vision, urinary retention, tachycardia, confusion and worsening constipation. Particular caution is required in patients with cognitive impairment, impulsivity, medication misadventure risk, glaucoma, urinary retention, cardiovascular disease, severe constipation or ileus risk.
A pragmatic approach is to prescribe the lowest effective dose, avoid vague “use as directed” instructions, specify the exact number of drops and frequency, advise that the solution must not be swallowed or taken directly from the bottle, and review ongoing need regularly.
Evidence from Systematic Review and Meta-analysis for Antipsychotic Induced Sialorrhoea: [Fornaro et al., 2023]
Efficacy for sialorrhea is most consistent for the following agents from highest to lowest: (note this is not specific for clozapine-related sialorrhoea).
- Metoclopramide
- Cyproheptadine
- Sulpiride
- Propantheline
- Diphenhydramine
- Benzhexol
- Doxepin
- Amisulpride
- Chlorpheniramine
- Amitriptyline
- Atropine ( not for nocturnal sialorrhea)
SUMMARY OF PHARMACOLOGICAL MANAGEMENT FOR CLOZAPINE INDUCED HYPERSALIVATION (SIALORRHOEA)
FAQs
1. What is clozapine-induced hypersalivation?
Clozapine-induced hypersalivation, also known as clozapine-induced sialorrhoea, is excessive salivation or drooling that occurs in patients taking clozapine. It may occur during the day or night and can cause social embarrassment, sleep disruption, poor adherence, and in severe cases aspiration risk.
2. How common is clozapine-induced hypersalivation?
Clozapine-induced hypersalivation is common, with the article noting that approximately 30–80% of patients report hypersalivation, and one study reported a rate as high as 91%.
3. Why is clozapine-induced sialorrhoea clinically important?
Clozapine-induced sialorrhoea is clinically important because it can cause distress, low self-esteem, insomnia, social embarrassment, aspiration pneumonia, and non-adherence to clozapine. This matters because clozapine is often essential in treatment-resistant schizophrenia.
4. What causes clozapine-induced hypersalivation?
The mechanisms are multifactorial and may include M4 muscarinic receptor agonism, alpha-2 receptor antagonism, unopposed beta-adrenoceptor activity, decreased laryngeal peristalsis, and reduced swallowing due to gastrointestinal hypomotility.
5. How should clozapine-induced hypersalivation be assessed?
Assessment should include severity, timing, daytime versus nocturnal symptoms, impact on sleep and adherence, aspiration risk, clozapine dose, clozapine plasma level, smoking status, interacting medications, and anticholinergic burden. Rating tools such as the Nocturnal Hypersalivation Rating Scale and Drooling Severity and Frequency Scale may be useful.
6. What non-pharmacological strategies help clozapine-induced hypersalivation?
Non-pharmacological strategies include chewing sugarless gum during the day to promote swallowing, covering the pillow with a towel at night, elevating the head, and sleeping on the side to reduce sleep disruption and aspiration risk.
7. Should the clozapine dose be reviewed in hypersalivation?
Yes. Clozapine-induced hypersalivation may be dose-related, so clinicians should review the clozapine dose, clozapine plasma level, and any medications that increase clozapine levels. Dose reduction may be considered where clinically safe, with close monitoring for relapse.
8. What medications are used for clozapine-induced hypersalivation?
Pharmacological options include sublingual atropine, hyoscine, other anticholinergic agents, and selected augmentation strategies. The article also discusses amisulpride 100–400 mg/day as a proposed alternative to anticholinergic agents in selected cases.
9. Is sublingual atropine used for clozapine-induced sialorrhoea?
Yes. Sublingual atropine drops are used off-label for clozapine-induced sialorrhoea and may have less systemic anticholinergic effect than oral anticholinergic agents. Clinicians should still monitor for anticholinergic adverse effects and practical dosing issues.
10. What are the risks of anticholinergic treatment in clozapine-induced hypersalivation?
Anticholinergic treatment may worsen clozapine-related adverse effects such as constipation, gastrointestinal hypomotility, cognitive impairment, blurred vision, urinary retention, and sedation. This is particularly important because constipation and ileus can be serious clozapine-related complications.
11. Can clozapine-induced hypersalivation improve over time?
Yes. Clozapine-induced hypersalivation often occurs early in treatment and may reduce in severity over time, so a “wait and watch” approach may be reasonable in mild cases while monitoring distress, sleep disruption, aspiration risk, and adherence.
12. Where can clinicians upskill in clozapine management and psychopharmacology?
For psychiatrists, GPs, nurse practitioners, pharmacists, and mental health professionals seeking to upskill in clozapine management, treatment-resistant schizophrenia, psychopharmacology, adverse-effect management, and antipsychotic prescribing, explore the relevant expert-led CPD courses and learning modules on The Academy by Psych Scene.
Schizophrenia: Advanced Clinical Approaches & Training for Psychiatrists
Get Serious About Psychiatry Learning
Our courses offer practical knowledge and clinical expertise at exceptional value, plus CME & CPD points.
Go to Academy by Psych Scene
